No credit card. No commitment.
5000+ G2 reviews
NurExone Biologic (TSXV: NRX) (FSE: J90)
Research
Founded in 2020
Haifa, Haifa District
nurexone.comNurExone Biologic (TSXV: NRX) (FSE: J90)
ResearchFounded in 2020Haifa, Haifa District
EmployeesNurExone Biologic (TSXV: NRX) (FSE: J90)'s financial review
Employees
13
Total Funding
1.3M
Last Funding Round
1.1M
NurExone Biologic (TSXV: NRX) (FSE: J90) information
NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System.The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.
NurExone Biologic (TSXV: NRX) (FSE: J90) industries
Research
Biotechnology research
NurExone Biologic (TSXV: NRX) (FSE: J90)'s financial review
Employees
13
Total Funding
1.3M
Last Funding Round
1.1M
Employee Metrics
Technologies
Email Providers
Other
Tag Management
Other
Captcha
Analytics and Tracking
Notable Alumni
Employees
Head of Bioprocess Development
Head of CMC ,Quality and Regulatory
Research And Development Scientist
R&D Student
Prospect on LinkedIn
Find verified emails and direct dial mobile numbers of contacts on LinkedIn, and sync them with your CRM instantly
Download Extension
Why our clients choose Apollo
“Apollo completely changed the game for us. It allowed us to identify relevant targets that are ready to scale and reach out to them at the exact right time.”
Erik Straub
Head of Product, Kickfurther
“Using Apollo.io, we've solved the biggest problem for every business, the lead problem. We are now constrained by sales time and no longer lack interested prospects.”
Michael Transon
CEO, Victorious
